Review on Characteristics and Analytical Methods of Rivaroxaban

References

• Kvasnicka, T.; Malikova, I.; Zenahlikova, Z.; Kettnerova, K.; Brzezkova, R.; Zima, T.; Ulrych, J.; Briza, J.; Netuka, I.; Kvasnicka, J. Rivaroxaban - Metabolism, Pharmacologic Properties and Drug Interactions. Curr. Drug Metab. 2017, 18, 636–642. DOI: https://doi.org/10.2174/1389200218666170518165443.
   PubMed Web of Science ®Google Scholar
• Bainey, K. R.; Welsh, R. C.; Connolly, S. J.; Marsden, T.; Bosch, J.; Fox, K. A. A.; Steg, P. G.; Vinereanu, D.; Connolly, D. L.; Berkowitz, S. D.; et al. Rivaroxaban plus Aspirin versus Aspirin Alone in Patients with Prior Percutaneous Coronary Intervention (COMPASS-PCI). Circulation 2020, 141, 1141–1151. DOI: https://doi.org/10.1161/circulationaha.119.044598.
   PubMed Web of Science ®Google Scholar
• Bonaca, M. P.; Bauersachs, R. M.; Anand, S. S.; Debus, E. S.; Nehler, M. R.; Patel, M. R.; Fanelli, F.; Capell, W. H.; Diao, L.; Jaeger, N.; et al. Rivaroxaban in Peripheral Artery Disease after Revascularization. N. Engl. J. Med. 2020, 382, 1994–2004. DOI: https://doi.org/10.1056/NEJMoa2000052.
   PubMed Web of Science ®Google Scholar
• Bonde, A. N.; Martinussen, T.; Lee, C. J.; Lip, G. Y. H.; Staerk, L.; Bang, C. N.; Bhattacharya, J.; Gislason, G.; Torp-Pedersen, C.; Olesen, J. B.; Hlatky, M. A. Rivaroxaban versus Apixaban for Stroke Prevention in Atrial Fibrillation: An Instrumental Variable Analysis of a Nationwide Cohort. Circ. Cardiovasc. Qual. Outcomes 2020, 13, e006058. DOI: https://doi.org/10.1161/circoutcomes.119.006058.
   PubMedGoogle Scholar
• Lim, G. B. Rivaroxaban Prevents VTE in Orthopaedic surgery. Nat. Rev. Cardiol. 2020, 17, 320 DOI: https://doi.org/10.1038/s41569-020-0377-9.
   Google Scholar
• Malik, A. H.; Yandrapalli, S.; Shetty, S.; Frishman, W. H.; Aronow, W. S. Rivaroxaban in Patients with Heart Failure and Sinus Rhythm: Meta-Analysis of Randomized Controlled Trials. Am. J. Ther. 2020. DOI: https://doi.org/10.1097/mjt.0000000000001117.
   Google Scholar
• Petersohn, S.; Pouwels, X.; Ramaekers, B.; Ten Cate-Hoek, A.; Joore, M. Rivaroxaban plus Aspirin for the Prevention of Ischaemic Events in Patients with Cardiovascular Disease: A cost-effectiveness study. Eur. J. Prev. Cardiol. 2020, 27, 1354–1365. DOI: https://doi.org/10.1177/2047487320913380.
   PubMedGoogle Scholar
• Young, G.; Lensing, A. W. A.; Monagle, P.; Male, C.; Thelen, K.; Willmann, S.; Palumbo, J. S.; Kumar, R.; Nurmeev, I.; Hege, K.; et al. Rivaroxaban for Treatment of Pediatric Venous Thromboembolism. An Einstein-Jr Phase 3 Dose-Exposure-Response Evaluation. J. Thromb. Haemost. 2020, 18, 1672–1685. DOI: https://doi.org/10.1111/jth.14813.
   PubMed Web of Science ®Google Scholar
• Vanassche, T.; Vandenbriele, C.; Peerlinck, K.; Verhamme, P. Pharmacotherapy with Oral Xa Inhibitors for Venous Thromboembolism. Expert Opin. Pharmacother. 2015, 16, 645–658. DOI: https://doi.org/10.1517/14656566.2015.999043.
   PubMed Web of Science ®Google Scholar
• Khan, S. U.; Khan, M. Z.; Asad, Z. U. A.; Valavoor, S.; Khan, M. U.; Khan, M. S.; Krupica, T.; Alkhouli, M.; Kaluski, E. Efficacy and Safety of Low Dose Rivaroxaban in Patients with Coronary Heart Disease: A Systematic Review and Meta-Analysis. J. Thromb. Thrombolysis 2020, 50, 913-920. DOI: https://doi.org/10.1007/s11239-020-02114-7.
   PubMedGoogle Scholar
• Khan, Y.; Zaidi, S. O.; Razak, B. S.; Zaki, M.; Malik, B. H. Use of New Oral Anticoagulants / Direct Oral Anticoagulants in Malignant Patients. Cureus 2020, 12, e7007. DOI: https://doi.org/10.7759/cureus.7007.
   PubMedGoogle Scholar
• Kim, J. H.; Seo, S.; Kim, K. P.; Chang, H. M.; Ryoo, B. Y.; Yoo, C.; Jeong, J. H.; Lee, J. L.; Im, H. S.; Jeong, H.; et al. Rivaroxaban versus Low-molecular-weight Heparin for Venous Thromboembolism in Advanced Upper Gastrointestinal Tract and Hepatopancreatobiliary Cancer. In Vivo 2020, 34, 829–837. DOI: https://doi.org/10.21873/invivo.11845.
   PubMedGoogle Scholar
• Liang, Y.; Zhu, J.; Liu, L.; Anand, S. S.; Connolly, S. J.; Bosch, J.; Guzik, T. J.; O'Donnell, M.; Dagenais, G. R.; Fox, K. A. A.; et al. Efficacy and Safety of Rivaroxaban plus Aspirin in Women and Men with Chronic Coronary or Peripheral Artery Disease. Cardiovasc. Res. 2020. DOI: https://doi.org/10.1093/cvr/cvaa100.
   Google Scholar
• Noohi, F.; Sadeghipour, P.; Kordrostami, S.; Shafe, O.; Maleki, M.; Kyavar, M.; Bakhshandeh, H.; Rezaei, Y.; Rokni, M.; Moosavi, J.; et al. Rivaroxaban in Patients Undergoing Surgical Mitral Valve Repair. J. Thromb. Thrombolysis 2020, 49, 475–479. DOI: https://doi.org/10.1007/s11239-020-02046-2.
   PubMedGoogle Scholar
• Weir, M. R.; Ashton, V.; Moore, K. T.; Shrivastava, S.; Peterson, E. D.; Ammann, E. M. Rivaroxaban versus Warfarin in Patients with Nonvalvular Atrial Fibrillation and Stage IV-V Chronic Kidney Disease. Am. Heart J. 2020, 223, 3–11. DOI: https://doi.org/10.1016/j.ahj.2020.01.010.
   PubMed Web of Science ®Google Scholar
• Song, Z. K.; Cao, H.; Wu, H.; Wei, Q.; Tang, M.; Yang, S.; Liu, Y.; Qin, L. Current Status of Rivaroxaban in Elderly Patients with Pulmonary Embolism (Review). Exp. Ther. Med. 2020, 19, 2817–2825. DOI: https://doi.org/10.3892/etm.2020.8559.
   PubMedGoogle Scholar
• Petkovic, A.; Al-Khalili, F.; Antovic, A.; Ammar, M.; Pruner, I.; Vranic, A.; Soutari, N.; Zdravkovic, N.; Malmstrom, R. E.; Jakovljevic, V.; Antovic, J. P. Effects of Rivaroxaban and Dabigatran on Global Hemostasis in Patients with Atrial Fibrillation. Blood Coagul. Fibrin. 2020, 31, 243–252. DOI: https://doi.org/10.1097/mbc.0000000000000907.
   PubMedGoogle Scholar
• Konicki, R.; Weiner, D.; Patterson, J. H.; Gonzalez, D.; Kashuba, A.; Cao, Y. C.; Gehi, A. K.; Watkins, P.; Powell, J. R. Rivaroxaban Precision Dosing Strategy for Real-World Atrial Fibrillation Patients. Clin. Transl. Sci. 2020, 13, 777–784. DOI: https://doi.org/10.1111/cts.12766.
   PubMedGoogle Scholar
• Çelebier, M.; Reçber, T.; Koçak, E.; Altinöz, S. RP-HPLC Method Development and Validation for Estimation of Rivaroxaban in Pharmaceutical Dosage Forms. Braz. J. Pharm. Sci. 2013, 49, 359–366. DOI: https://doi.org/10.1590/S1984-82502013000200018.
   Google Scholar
• Süslü, İ.; Çelebier, M.; Altınöz, S. Electrochemical Behaviour Investigation and Square-Wave Voltammetric Determination of Rivaroxaban in Pharmaceutical Dosage Forms. Anal. Methods 2014, 6, 9397–9403. DOI: https://doi.org/10.1039/C4AY01871K.
   Google Scholar
• Çelebier, M.; Reçber, T.; Koçak, E.; Altınöz, S.; Kır, S. Determination of Rivaroxaban in Human Plasma by Solid-Phase Extraction–High Performance Liquid Chromatography. J. Chromatogr. Sci. 2016, 54, 216–220. DOI: https://doi.org/10.1093/chromsci/bmv135.
   PubMed Web of Science ®Google Scholar
• Çelebier, M.; Kaynak, M. S.; Altınöz, S.; Sahin, S. UV Spectrophotometric Method for Determination of the Dissolution Profile of Rivaroxaban. Dissolution. Technol. 2014, 21, 56–59. DOI: https://doi.org/10.14227/DT210414P56.
   Google Scholar
• Muralikrishna, K. Spectrophotometric Method for Determination of Rivaroxaban in Bulk and Tablet Formulation and Its Validation. Inventi Rapid: Pharm Anal. Qual. Assur. 2013. DOI: Inventi:ppaqa/699/13.
   Google Scholar
• Sekaran, C. B.; Bind, V. H.; Damayanthi, M. R.; Sireesha, A. Development and Validation of UV Spectrophotometric Method for the Determination of Rivaroxaban. Der Pharma Chem 2013, 5, 1–5.
   Google Scholar
• Pinaz, A. K.; Muralikrishna, K. Area under Curve Spectrophotometric Method for Determination of Rivaroxaban in Bulk and Tablet Formulation and Its Validation. Asian J. Res. Pharm. 2013, 3, 109–113.
   Google Scholar
• Seshamamba, B.; Sekaran, C. Spectrophotometric Quantification of Direct Factor xa Inhibitor, Rivaroxaban, in Raw and Tablet Dosage Form. Glob. Drugs Ther. 2017, 2, 1–8. DOI: https://doi.org/10.15761/GDT.1000122.
   Google Scholar
• Seshamamba, B. S. V.; Sekaran, C. B. Spectrophotometric Analysis for the Quantification of Rivaroxaban in Bulk and Tablet Dosage Form. Int. J. Med. Pharm. Sci. 2017, 7, 21–34.
   Google Scholar
• El-Bagary, R. I.; Elkady, E. F.; Farid, N. A.; Youssef, N. F. A Validated Spectrophotometric Method and Thermodynamic Studies for the Determination of Cilostazol and Rivaroxaban in Pharmaceutical Preparations Using Fe-Phenanthroline System. Anal. Chem. Lett. 2017, 7, 676–688. DOI: https://doi.org/10.1080/22297928.2017.1385420.
   Google Scholar
• Kasad, P. A.; Muralikrishna, K. Design and Validation of Dissolution Profile of Rivaroxaban by Using RP-HPLC Method in Dosage Form. Asian J. Pharm. 2013, 3, 75–78.
   Google Scholar
• Pinaz, A. K.; Muralikrishna, K. Method Development and Acid Degradation Study of Rivaroxaban by RP-HPLC in Bulk. Asian J. Pharm. 2013, 3, 62–65.
   Google Scholar
• Lories, I.; Mostafa, A.; Girges, M. High Performance Liquid Chromatography, TLC Densitometry, First Derivative and First Derivative Ratio Spectrophotometry for Determination of Rivaroxaban and Its Alkaline Degradates in Bulk Powder and Its Tablets. Chromatogr. Sep. Tech. 2013, 4, 1–6. DOI: https://doi.org/10.4172/2157-7064.1000202.
   Google Scholar
• Seshamamba, B. S. V.; Satyanarayana, P. V. V.; Sekaran, C. B. Application of Stability Indicating HPLC Method with UV Detector to the Analysis of Rivaroxaban in Bulk and Tablet Dosage Form. Chem. Sci. Trans. 2014, 3, 1546–1554. DOI: https://doi.org/10.7598/cst2014.893.
   Google Scholar
• Ramisetti, N. R.; Kuntamukkala, R. Development and Validation of a Stability Indicating LC-PDA-MS/MS Method for Separation, Identification and Characterization of Process Related and Stress Degradation Products of Rivaroxaban. RSC Adv. 2014, 4, 23155–23167. DOI: https://doi.org/10.1039/c4ra00744a.
   Google Scholar
• Prabhune, S. S.; Dighe, V.; Pradhan, N. S. Enantiomeric Separation of Rivaroxaban by a Chiral Liquid Chromatographic Method. Int. J. Pharm. Pharm. Sci. 2015, 7, 399–402.
   Google Scholar
• Walter, M. E.; Perobell, R.; Da Silva, F. S.; Cardoso Junior, C. D.; da Silva, I. S.; Dalmora, S. L. Development and Validation of a Stability-Indicating RP-HPLC Method for the Determination of Rivaroxaban in Pharmaceutical Formulations. Lat. Am. J. Pharm. 2015, 34, 1503–1510.
   Web of Science ®Google Scholar
• Hadagali, M. Determination of Rivaroxaban in Pure, Pharmaceutical Formulations and Human Plasma Samples by RP-HPLC. Int. J. Adv. Pharm. Anal. 2015, 5, 65–68. DOI: https://doi.org/10.7439/ijapa.v5i3.2800.
   Google Scholar
• Souri, E.; Mottaghi, S.; Zargarpoor, M.; Ahmadkhaniha, R.; Jalalizadeh, H. Development of a Stability-Indicating HPLC Method and a Dissolution Test for Rivaroxaban Dosage Forms. Acta Chromatogr. 2016, 28, 347–361. DOI: https://doi.org/10.1556/1326.2016.28.3.05.
   Web of Science ®Google Scholar
• Arous, B.; Al-Mardini, M. A.; Karabet, F.; Daghestani, M.; Al-Lahham, F.; Al-Askar, A. Development and Validation of a Liquid Chromatography Method for the Analysis of Rivaroxaban and Determination of Its Production Related Impurities. Pharm. Chem. J. 2018, 52, 483–490. DOI: https://doi.org/10.1007/s11094-018-1844-z.
   Web of Science ®Google Scholar
• Girase, Y.; Srinivasrao, V.; Soni, D. Development and Validation of Stability-Indicating RP-HPLC Method for Rivaroxaban and Its Impurities. Sojb. 2018, 4, 1–6. DOI: https://doi.org/10.4236/ajac.2015.66052.
   Google Scholar
• Badroon, T.; Sreeramulu, J. Development and Validation of Stability Indicating Assay by HPLC Method for Estimation of Rivaroxaban. Int. J. Pharma Bio Sci. 2019, 8, 2582–2586. DOI: https://doi.org/10.21746/ijbpr.2019.8.5.5.
   Google Scholar
• Arous, B.; Al-Mardini, M. A.; Ghazal, H.; Al-Lahham, F. Stability-Indicating Method for the Determination of Rivaroxaban and Its Degradation Products Using LC-MS and TLC. Res. J. Pharm. Technol. 2018, 11, 212–220. DOI: https://doi.org/10.5958/0974-360X.2018.00040.9.
   Google Scholar
• R.; Wingert, N.; A. G.; Nunes, M.; T.; Barden, A.; Gomes, P.; I.; Muller, E.; M. M.; Flores, E.; Steppe, M. Ultra-Performance LC-ESI/Q-TOF MS for the Rapid Analysis of Rivaroxaban: Method Validation Using Experimental Design for Robustness Evaluation. Curr. Anal. Chem. 2015, 11, 124–129. DOI: https://doi.org/10.2174/1573411011666150121224018.
   Google Scholar
• Elesbao Walter, M.; Ferreira Perobelli, R.; Gustavo Jung Motta, L.; Rosa da Silveira, A.; Xavier, B.; LuizDalmora, S. Micellar Electrokinetic Capillary Method for the Analysis of Rivaroxaban and Its Correlation with RP–LC Method and Bioassay. Curr. Anal. Chem. 2017, 13, 379–385. DOI: https://doi.org/10.2174/1573411012666161025150131.
   Google Scholar
• Wingert, N. R.; Dos Santos, N. O.; Campanharo, S. C.; Jablonski, A.; Steppe, M. Quantitative Assessment of Poorly Soluble Anticoagulant Rivaroxaban by Microemulsion Electrokinetic Chromatography. J. Chromatogr. Sci. 2018, 56, 650–655. DOI: https://doi.org/10.1093/chromsci/bmy036.
   PubMedGoogle Scholar
• Vaghela, D.; Patel, P. High Performance Thin Layer Chromatographic Method with Densitometry Analysis for Determination of Rivaroxaban from Its Tablet Dosage Form. Int. J. Pharm. Pharma Sci. 2014, 6, 383–386.
   Google Scholar
• Alam, P.; Ezzeldin, E.; Iqbal, M.; Anwer, M. K.; Mostafa, G. A.; Alqarni, M. H.; Foudah, A. I.; Shakeel, F. Ecofriendly Densitometric RP-HPTLC Method for Determination of Rivaroxaban in Nanoparticle Formulations Using Green Solvents. RSC Adv. 2020, 10, 2133–2140. DOI: https://doi.org/10.1039/C9RA07825H.
   PubMed Web of Science ®Google Scholar
• EMEA, Guideline on the Investigation of Bioequivalance. Use, C. f. M. P. f. H., Ed. European Medicines Agency: London, 31 January 2009.
   Google Scholar
• FDA, Dissolution Testing of Immediate Release Solid Oral Dosage Forms. (CDER), C. f. D. E. a. R., Ed. U.S. Department of Health and Human Services Food and Drug Administration: Rockville, MD, August 1997.
   Google Scholar
• Li, W.; Jian, W.; Fu, Y. Basic Sample Preparation Techniques in LC‐MS Bioanalysis: Protein Precipitation, Liquid–Liquid Extraction, and Solid‐Phase Extraction. In Sample Preparation in LC‐MS Bioanalysis, Fu, W. L. W. J. Y., Ed. John Wiley & Sons, Inc.: New Jersey, U.S., 2019; pp 1–30.
   Google Scholar
• Medvedovici, A.; Bacalum, E.; David, V. Sample Preparation for Large‐Scale Bioanalytical Studies Based on Liquid Chromatographic Techniques. Biomed. Chromatogr. 2018, 32, e4137. DOI: https://doi.org/10.1002/bmc.4137.
   Google Scholar
• Magiera, S.; Hejniak, J.; Baranowski, J. Comparison of Different Sorbent Materials for Solid-Phase Extraction of Selected Drugs in Human Urine Analyzed by UHPLC–UV. J. Chromatogr. B 2014, 958, 22–28. DOI: https://doi.org/10.1016/j.jchromb.2014.03.014.
   PubMedGoogle Scholar
• Gouveia, F.; Bicker, J.; Santos, J.; Rocha, M.; Alves, G.; Falcão, A.; Fortuna, A. Development, Validation and Application of a New HPLC-DAD Method for Simultaneous Quantification of Apixaban, Dabigatran, Edoxaban and Rivaroxaban in Human Plasma. J. Pharm. Biomed. Anal. 2020, 181, 1–11. DOI: https://doi.org/10.1016/j.jpba.2020.113109.
   Google Scholar
• Ferrone, V.; Todaro, S.; Carlucci, M.; Fontana, A.; Ventrella, A.; Carlucci, G.; Milanetti, E. Optimization by Response Surface Methodology of a Dispersive Magnetic Solid Phase Extraction Exploiting Magnetic Graphene Nanocomposite Coupled with UHPLC-PDA for Simultaneous Determination of New Oral Anticoagulants (NAOs) in Human Plasma. J. Pharm. Biomed. Anal. 2020, 179, 112992. DOI: https://doi.org/10.1016/j.jpba.2019.112992.
   PubMedGoogle Scholar
• Cini, M.; Legnani, C.; Padrini, R.; Cosmi, B.; Dellanoce, C.; De Rosa, G.; Marcucci, R.; Pengo, V.; Poli, D.; Testa, S.; Palareti, G. DOAC Plasma Levels Measured by Chromogenic anti‐Xa Assays and HPLC‐UV in Apixaban‐and Rivaroxaban‐Treated Patients from the START‐Register. Int. J. Lab. Hematol. 2020, 42, 214–222. DOI: https://doi.org/10.1111/ijlh.13159.
   PubMedGoogle Scholar
• El-Aziz, H. A.; Ibrahim, F. M.; Me, S. E.-D. F. Micellar High Performance Liquid Chromatographic Determination of a Binary Mixture of Rivaroxaban and Clopidogrel and Application to Biological Fluids. Pharm. Anal. Acta 2016, 7, 1–11. DOI: https://doi.org/10.4172/2153-2435.1000506.
   Google Scholar
• Albiol-Chiva, J.; Peris-Vicente, J.; García-Ferrer, D.; Esteve-Romero, J. Micellar Liquid Chromatography Determination of Rivaroxaban in Plasma and Urine. Validation and Theoretical Aspects. J. Chromatogr. B 2019, 1120, 8–15. DOI: https://doi.org/10.1016/j.jchromb.2019.04.040.
   PubMedGoogle Scholar
• Rohde, G. Determination of Rivaroxaban–A Novel, Oral, Direct Factor Xa Inhibitor–in Human Plasma by High-Performance Liquid Chromatography–Tandem Mass Spectrometry. J. Chromatogr. B 2008, 872, 43–50. DOI: https://doi.org/10.1016/j.jchromb.2008.07.015.
   PubMed Web of Science ®Google Scholar
• Schmitz, E.; Boonen, K.; Van Den Heuvel, D.; Van Dongen, J.; Schellings, M.; Emmen, J.; Van Der Graaf, F.; Brunsveld, L.; Van De Kerkhof, D. Determination of Dabigatran, Rivaroxaban and Apixaban by Ultra-Performance Liquid Chromatography - Tandem Mass Spectrometry (UPLC-MS/MS) and Coagulation Assays for Therapy Monitoring of Novel Direct Oral Anticoagulants. J. Thromb. Haemost. 2014, 12, 1636–1646. DOI: https://doi.org/10.1111/jth.12702.
   PubMed Web of Science ®Google Scholar
• Korostelev, M.; Bihan, K.; Ferreol, L.; Tissot, N.; Hulot, J.-S.; Funck-Brentano, C.; Zahr, N. Simultaneous Determination of Rivaroxaban and Dabigatran Levels in Human Plasma by High-Performance Liquid Chromatography-Tandem Mass Spectrometry. J. Pharm. Biomed. Anal. 2014, 100, 230–235. DOI: https://doi.org/10.1016/j.jpba.2014.08.011.
   PubMed Web of Science ®Google Scholar
• Bardy, G.; Fischer, F.; Appert, A.; Baldin, B.; Stève, M.; Spreux, A.; Lavrut, T.; Drici, M.-D. Is anti-Factor Xa Chromogenic Assay for Rivaroxaban Appropriate in Clinical Practice? Advantages and Comparative Drawbacks. Throm. Res. 2015, 136, 396–401. DOI: https://doi.org/10.1016/j.thromres.2015.05.015.
   PubMedGoogle Scholar
• Iqbal, M.; Khalil, N. Y.; Imam, F.; Anwer, M. K. A Validated High-Throughput UHPLC-MS/MS Assay for Accurate Determination of Rivaroxaban in Plasma Sample. J. Thromb. Thrombolysis. 2015, 39, 79–88. DOI: https://doi.org/10.1007/s11239-014-1121-2.
   PubMedGoogle Scholar
• Kuhn, J.; Gripp, T.; Flieder, T.; Dittrich, M.; Hendig, D.; Busse, J.; Knabbe, C.; Birschmann, I. UPLC-MRM Mass Spectrometry Method for Measurement of the Coagulation Inhibitors Dabigatran and Rivaroxaban in Human Plasma and Its Comparison with Functional Assays. PLoS One 2015, 10, e0145478. DOI: https://doi.org/10.1371/journal.pone.0145478.
   PubMed Web of Science ®Google Scholar
• Derogis, P. B. M.; Sanches, L. R.; de Aranda, V. F.; Colombini, M. P.; Mangueira, C. L. P.; Katz, M.; Faulhaber, A. C. L.; Mendes, C. E. A.; Ferreira, C. E. D. S.; França, C. N.; Guerra, J. C. d C. Determination of Rivaroxaban in Patient’s Plasma Samples by anti-Xa Chromogenic Test Associated to High Performance Liquid Chromatography Tandem Mass Spectrometry (HPLC-MS/MS). PLoS One 2017, 12, e0171272. DOI: https://doi.org/10.1371/journal.pone.0171272.
   PubMedGoogle Scholar
• Varga, A.; Șerban, R. C.; Muntean, D. L.; Tătar, C. M.; Farczadi, L.; Tilea, I. Rapid Liquid Chromatography Tandem Mass Spectrometry Determination of Rivaroxaban Levels in Human Plasma for Therapeutic Drug Monitoring. Rev. Rom. Med. Lab. 2017, 25, 145–155. DOI: https://doi.org/10.1515/rrlm-2017-0007.
   Google Scholar
• Lagoutte-Renosi, J.; Le Poupon, J.; Girard, A.; Montange, D.; Davani, S. A Simple and Fast HPLC-MS/MS Method for Simultaneous Determination of Direct Oral Anticoagulants Apixaban, Dabigatran, Rivaroxaban in Human Plasma. J. Chromatogr. B 2018, 1100–1101, 43–49. DOI: https://doi.org/10.1016/j.jchromb.2018.09.026.
   PubMed Web of Science ®Google Scholar
• Thom, I.; Cameron, G.; Robertson, D.; Watson, H. Measurement of Rivaroxaban Concentrations Demonstrates Lack of Clinical Utility of a PT, dPT and APTT Test in Estimating Levels. Int. J. Lab. hematol. 2018, 40, 493–499. DOI: https://doi.org/10.1111/ijlh.12846.
   PubMedGoogle Scholar
• Rodina, T.; Mel’nikov, E.; Aksenov, A.; Belkov, S.; Sokolov, A.; Prokof’ev, A.; Ramenskaya, G. Development of an HPLC-MS/MS Method for Quantitative Determination of Rivaroxaban in Human Blood Serum. Pharm. Chem. J. 2018, 52, 372–377. DOI: https://doi.org/10.1007/s11094-018-1824-3.
   Google Scholar
• Foerster, K. I.; Huppertz, A.; Meid, A. D.; Müller, O. J.; Rizos, T.; Tilemann, L.; Haefeli, W. E.; Burhenne, J. Dried-Blood-Spot Technique to Monitor Direct Oral Anticoagulants: Clinical Validation of a UPLC-MS/MS-Based Assay. Anal. Chem. 2018, 90, 9395–9402. DOI: https://doi.org/10.1021/acs.analchem.8b02046.
   PubMed Web of Science ®Google Scholar
• de Aranda, V.; Derogis, P.; Sanches, L.; Mangueira, C.; Katz, M.; Faulhaber, A.; Mendes, C.; Ferreira, C.; França, C.; Guerra, J.; Research, B. Diagnostic Accuracy of Thromboelastometry and Its Correlation with the HPLC-MS/MS Quantification Test. Braz. J. Med. Biol. Res. 2019, 52, 1–9. DOI: https://doi.org/10.1590/1414-431x20198006.
   Google Scholar
• Slavik, L.; Jacova, J.; Friedecky, D.; Ulehlova, J.; Tauber, Z.; Prochazkova, J.; Hlusi, A.; Palova, M. Evaluation of the DOAC-Stop Procedure by LC-MS/MS Assays for Determining the Residual Activity of Dabigatran, Rivaroxaban, and Apixaban. Clin. Appl. Thromb. Hemost. 2019, 25, 1076029619872556 DOI: https://doi.org/10.1177/1076029619872556.
   Google Scholar
• Zhao, Y.; Couchman, L.; Kipper, K.; Arya, R.; Patel, J. P. A UHPLC-MS/MS Method to Simultaneously Quantify Apixaban, Edoxaban and Rivaroxaban in Human Plasma and Breast Milk: For Emerging Lactation Studies. J. Chromatogr. B 2020, 1144, 1–7. DOI: https://doi.org/10.1016/j.jchromb.2020.122095.
   Google Scholar
• Reddy, G. S.; Reddy, S. N. P.; Reddy, L. S. K. Development and Validation of HPLC-MS/MS Method for Rivaroxaban Quantitation in Human Plasma Using Solid Phase Extraction Procedure. Orient. J. Chem. 2016, 32, 1145–1154. DOI: https://doi.org/10.13005/ojc/320240.
   Google Scholar
• Foerster, K. I.; Huppertz, A.; Müller, O. J.; Rizos, T.; Tilemann, L.; Haefeli, W. E.; Burhenne, J. Simultaneous Quantification of Direct Oral Anticoagulants Currently Used in Anticoagulation therapy. J. Pharm. Biomed. Anal. 2018, 148, 238–244. DOI: https://doi.org/10.1016/j.jpba.2017.10.011.
   PubMed Web of Science ®Google Scholar
• Shaikh, K.; Mungantiwar, A.; Halde, S.; Pandita, N. Liquid Chromatography–Tandem Mass Spectrometry Method for Determination of Rivaroxaban in Human Plasma and Its Application to a Pharmacokinetic Study. J. Mass Spectrom. 2019, 20, 91–105. DOI: https://doi.org/10.1177/1469066719875014.
   Google Scholar
• Magiera, S. Fast, Simultaneous Quantification of Three Novel Cardiac Drugs in Human Urine by MEPS-UHPLC-MS/MS for Therapeutic Drug Monitoring. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 2013, 938, 86–95. DOI: https://doi.org/10.1016/j.jchromb.2013.09.001.
   PubMedGoogle Scholar
• Gous, T.; Couchman, L.; Patel, J. P.; Paradzai, C.; Arya, R.; Flanagan, R. J. Measurement of the Direct Oral Anticoagulants Apixaban, Dabigatran, Edoxaban, and Rivaroxaban in Human Plasma Using Turbulent Flow Liquid Chromatography with High-Resolution Mass Spectrometry. Ther. Drug Monit. 2014, 36, 597–605. DOI: https://doi.org/10.1097/FTD.0000000000000059.
   PubMed Web of Science ®Google Scholar
• Lee, H. C.; Kim, D. Y.; Choi, M.-J.; Jin, S. K.; Choi, Y. S. A Simple and Efficient Method to Determine Rivaroxaban in Rat Plasma Using Liquid-Liquid Extraction and LC-MRM. Mass Spectrom. Lett. 2019, 10, 66–70.
   Web of Science ®Google Scholar
• Szultka-Młyńska, M.; Bajkacz, S.; Kaca, M.; Baranowska, I.; Buszewski, B. Electrochemical Simulation of Three Novel Cardiovascular Drugs Phase I Metabolism and Development of a New Method for Determination of Them by Liquid Chromatography Coupled with Tandem Mass Spectrometry. J. Chromatogr. B 2018, 1093–1094, 100–112. DOI: https://doi.org/10.1016/j.jchromb.2018.07.002.
   PubMedGoogle Scholar
• Wang, L.; Gai, S.; Zhang, X.; Xu, X.; Gou, N.; Wang, X.; Zhou, N.; Feng, T. Simultaneous Determination of Rivaroxaban and TAK-438 in Rat Plasma by LC–MS/MS: Application to Pharmacokinetic Interaction Study. Bioanalysis 2020, 12, 11–22. DOI: https://doi.org/10.4155/bio-2019-0130.
   PubMedGoogle Scholar
• Cheng, Y. H.; Chen, W. C.; Chang, S. Y. Rapid Determination of Rivaroxaban in Human Urine and Serum Using Colloidal Palladium Surface-Assisted Laser Desorption/Ionization Mass Spectrometry. Rapid Commun. Mass Spectrom. 2015, 29, 1977–1983. DOI: https://doi.org/10.1002/rcm.7308.
   PubMed Web of Science ®Google Scholar
• Investigators, E. Oral Rivaroxaban for Symptomatic Venous Thromboembolism. N. Engl. J. Med. 2010, 363, 2499–2510. DOI: https://doi.org/10.1056/NEJMoa1007903.
   PubMed Web of Science ®Google Scholar